[go: up one dir, main page]

MX2021015826A - Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. - Google Patents

Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.

Info

Publication number
MX2021015826A
MX2021015826A MX2021015826A MX2021015826A MX2021015826A MX 2021015826 A MX2021015826 A MX 2021015826A MX 2021015826 A MX2021015826 A MX 2021015826A MX 2021015826 A MX2021015826 A MX 2021015826A MX 2021015826 A MX2021015826 A MX 2021015826A
Authority
MX
Mexico
Prior art keywords
pyrimidine
treating cancer
methods
pyridine compounds
inhibitory activity
Prior art date
Application number
MX2021015826A
Other languages
English (en)
Inventor
Bayard R Huck
Samantha M Goodstal
Claude Gimmi-Mckim
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2021015826A publication Critical patent/MX2021015826A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona métodos para el tratamiento del cáncer usando compuestos de pirimidina y piridina que son inhibidores de tirosina cinasa de Bruton (BTK, por sus siglas en inglés).
MX2021015826A 2015-11-04 2018-04-30 Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. MX2021015826A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250575P 2015-11-04 2015-11-04
US201662296143P 2016-02-17 2016-02-17
US201662341189P 2016-05-25 2016-05-25

Publications (1)

Publication Number Publication Date
MX2021015826A true MX2021015826A (es) 2022-02-03

Family

ID=57442803

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005461A MX2018005461A (es) 2015-11-04 2016-11-04 Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
MX2021015826A MX2021015826A (es) 2015-11-04 2018-04-30 Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018005461A MX2018005461A (es) 2015-11-04 2016-11-04 Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.

Country Status (23)

Country Link
US (3) US20170119766A1 (es)
EP (2) EP3371165B1 (es)
JP (4) JP6913100B2 (es)
KR (1) KR20180073599A (es)
CN (1) CN108779095A (es)
AU (3) AU2016349584B9 (es)
BR (1) BR112018007604B1 (es)
CA (1) CA3001735A1 (es)
CY (1) CY1125116T1 (es)
DK (1) DK3371165T3 (es)
ES (1) ES2912059T3 (es)
HU (1) HUE058323T2 (es)
IL (2) IL293093B2 (es)
LT (1) LT3371165T (es)
MX (2) MX2018005461A (es)
NZ (1) NZ741293A (es)
PL (1) PL3371165T3 (es)
RS (1) RS63146B1 (es)
RU (2) RU2022100782A (es)
SG (2) SG11201802927VA (es)
SI (1) SI3371165T1 (es)
TW (2) TWI783915B (es)
WO (1) WO2017079542A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2022100782A (ru) * 2015-11-04 2022-02-03 Мерк Патент Гмбх Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью
NZ741294A (en) * 2015-11-17 2023-07-28 Merck Patent Gmbh Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
AU2018263921A1 (en) * 2017-05-03 2019-12-05 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
CA3104191A1 (en) * 2018-06-19 2019-12-26 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
CR20210045A (es) 2018-07-25 2021-06-18 Novartis Ag Inhibidores de inflamasoma nlrp3
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
BR112023002031A2 (pt) 2020-08-14 2023-03-07 Novartis Ag Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
CN112250666B (zh) * 2020-10-09 2022-01-14 广东东阳光药业有限公司 取代的嘧啶类化合物及其用途
WO2022206939A1 (zh) * 2021-04-03 2022-10-06 海南耀臻生物医药科技有限公司 作为fgfr抑制剂的杂环化合物及其应用
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
WO2023247774A1 (en) 2022-06-24 2023-12-28 Merck Patent Gmbh Treatment regimen for autoimmune diseases and inflammatory diseases
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19649896A1 (de) * 1996-12-02 1998-06-04 Henkel Kgaa Geformte Seifenprodukte
TW520362B (en) * 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
JP4937112B2 (ja) * 2004-03-30 2012-05-23 バーテックス ファーマシューティカルズ インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
EP2211615A4 (en) * 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
SG194219A1 (en) * 2011-06-10 2013-11-29 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
TW201414734A (zh) * 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US8895750B2 (en) * 2013-03-14 2014-11-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
JP6494633B2 (ja) * 2013-09-22 2019-04-03 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されているアミノピリミジン化合物および使用方法
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
RU2022100782A (ru) * 2015-11-04 2022-02-03 Мерк Патент Гмбх Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью
NZ741294A (en) * 2015-11-17 2023-07-28 Merck Patent Gmbh Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity

Also Published As

Publication number Publication date
EP3371165A1 (en) 2018-09-12
ES2912059T3 (es) 2022-05-24
CN108779095A (zh) 2018-11-09
SI3371165T1 (sl) 2022-05-31
CA3001735A1 (en) 2017-05-11
PL3371165T3 (pl) 2022-05-02
US20200206224A1 (en) 2020-07-02
IL293093B1 (en) 2024-03-01
AU2021211982B2 (en) 2023-03-02
TW202320784A (zh) 2023-06-01
LT3371165T (lt) 2022-05-10
IL258979A (en) 2018-06-28
AU2016349584B2 (en) 2021-05-13
AU2021211982A1 (en) 2021-08-26
JP2018532805A (ja) 2018-11-08
HUE058323T2 (hu) 2022-07-28
TW201722430A (zh) 2017-07-01
RU2022100782A (ru) 2022-02-03
JP2023105214A (ja) 2023-07-28
MX2018005461A (es) 2018-08-01
TWI783915B (zh) 2022-11-21
BR112018007604A2 (pt) 2018-10-23
CY1125116T1 (el) 2024-12-13
JP2025023232A (ja) 2025-02-14
EP3371165B1 (en) 2022-01-26
AU2023203377A1 (en) 2023-06-29
IL258979B (en) 2022-06-01
IL293093B2 (en) 2024-07-01
BR112018007604B1 (pt) 2022-08-16
US20170119766A1 (en) 2017-05-04
RU2018120153A (ru) 2019-12-05
SG11201802927VA (en) 2018-05-30
AU2016349584B9 (en) 2021-06-03
US11491153B2 (en) 2022-11-08
US20210244736A1 (en) 2021-08-12
SG10202005292UA (en) 2020-07-29
IL293093A (en) 2022-07-01
NZ741293A (en) 2023-06-30
RS63146B1 (sr) 2022-05-31
JP6913100B2 (ja) 2021-08-04
TWI858413B (zh) 2024-10-11
WO2017079542A1 (en) 2017-05-11
RU2765154C2 (ru) 2022-01-26
RU2018120153A3 (es) 2020-03-05
EP4014977A1 (en) 2022-06-22
DK3371165T3 (da) 2022-05-02
JP2021165308A (ja) 2021-10-14
KR20180073599A (ko) 2018-07-02
AU2016349584A1 (en) 2018-04-26
JP7295169B2 (ja) 2023-06-20

Similar Documents

Publication Publication Date Title
MX2021015826A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
PH12018501268A1 (en) Compounds useful as kinase inhibitors
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
IL255831A (en) Inhibitors of bruton's tyrosine kinase
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
MY199705A (en) Heterocyclic compounds as immunomodulators
EA201791133A1 (ru) Ингибиторы erk
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
NZ738458A (en) Tyrosine kinase inhibitors
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
ZA202000148B (en) Heterocyclic inhibitors of atr kinase
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX367707B (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.